Endometriosis is a disorder in which endometrial tissue is found outside the uterus 27 causing pain, infertility and stress. Finding an effective and long-term treatment for 28 endometriosis still remains one of the most significant challenges in the field. Corticotropin 29 releasing hormone (CRH) is one of the main signaling peptides within the hypothalamic pituitary 30 adrenal (HPA) axis released in response to stress. CRH can affect nervous and visceral tissues 31 such as the uterus and gut via activation of two types of CRH receptors: CRHR1 and CRHR2.
120 endometriosis or sham surgery and were allowed to progress for 7 days. Rats in Group 2 121 received sham surgery or endometriosis. Rats from the endometriosis group were injected with 122 either vehicle or antalarmin for seven consecutive days after surgery and allowed to progress 123 for 53 additional days. During the endometriosis progression period, animals were undisturbed 124 except for weekly weighing done at the same time of cage changing.
125
126 Drug administration 127 Animals in Group 2 received 1 daily injection (between 09:00 -10:00 hours) for 7 7 138
Endometriosis was surgically induced as previously described elsewhere (29, 30) . Briefly, 139 rats were anesthetized with isoflurane and four pieces of the right uterine horn were auto 140 transplanted to 4 different blood vessels in the intestinal mesentery. The control group were sham 141 operated animals for which the right uterine horn was massaged for 2 minutes and sutures were 142 placed in the intestinal mesenteric area with no uterine implants. For group 1, sham or 143 endometriosis operated rats were allowed to progress for 7 days after surgery. For group 2, 144 endometriosis was allowed to progress for 60 days before sacrificing, similar to our previous report 145 (31;30).
146 Behavioral assessment 147 One day before behavioral assessment and sacrifice a subset of rats (6 vehicle and 6
148 antalarmin) were subjected to an acute episode of swim stress of 10 min and compared to no 149 stress controls to assess how rats respond to acute activation of the HPA axis. For this, animals 150 were placed in a Plexiglas tank for 10 min in water at 25°C (modified from (32)). 158 closest to the walls) and 5) total fecal pellets. The more time the animal spends in the center of 159 the arena compared to the space adjacent to the wall is considered as having less anxiety. At the 8 160 end of the testing period, animals were returned to the home cage and after a 5-min break were 161 tested in the elevated zero-maze.
162
The elevated zero-maze is very similar to the more traditional elevated plus maze test, 173 less anxiety. After the 5-min testing period, the rat was returned to the home cage and 174 immediately anesthetized with an overdose of 65% sodium pentobarbital to proceed with 175 laparotomy. The maze was thoroughly cleaned with 70% alcohol solution and allowed to dry 176 before testing the next rat.
Sample Collection and Processing 178
We verified that the animals were deeply anesthetized. Rats were weighed, and a 179 cytological smear taken to verify stage of the estrous cycle. The peritoneal and thoracic cavities 180 were opened, and a blood sample was collected directly from the heart. Following this, we 181 collected peritoneal fluid using a sterile plastic pipette. Then, we examined for the presence of 182 endometriosis vesicles. The implants that developed into vesicles were excised from the 11 227 <0.05 was considered statistically significant. The variability between groups was first assessed 228 followed by a test for outlier values. A Student t-test was used for comparisons between two 229 groups and when group variability was significantly different, a Welch corrected t-test was used.
230 A one-way analysis of variance (ANOVA) was used to compare behaviors. A one-sample t-test 231 against the sham rats value normalized to 1.0 was used to assess qRT-PCR results. A repeated 232 measures one-way ANOVA was used to compare changes in weight gain between treatment 233 groups across time.
234
235 Results
Shortly after endometriosis induction, CRHR1 is elevated 237
To evaluate the early endometriotic vesicle development, we induced the disease and 238 sacrificed the animals after 7 days. It is during this early development period that we 239 hypothesized that the major changes in CRHR1 will be observed. At 7 days, we observed that 240 93.7 % of the implants have created a large vesicle, which in most cases was very large and filled 241 with fluid. In the sham group, only sutures were observed as no uterus was transplanted. Table   242 1 shows the morphological characteristics of the observed vesicles at 7 days post-induction 243 surgery. We quantified the CRHR1 mRNA in the vesicles as compared to the normal uteri of the 244 same rats and that of sham surgery controls. CRHR1 mRNA in endometriosis vesicles showed a 245 two-fold increase as compared to normal uterus of sham rats (t=2.934, d.f.=6, p<0.05; Figure 2 ). In contrast, the mRNA levels in uteri of rats that received endometriosis were not different from 247 the uteri of sham rats (t=0.829, d.f.=6, p>0.05; Figure 2 ). At the time of sacrifice, we collected peritoneal fluid and blood serum from rats to later 317 examine how the treatment with antalarmin might have altered HPA axis markers and also the 318 pro-inflammatory cytokine IL-6. Corticosterone was slightly elevated in rats with endometriosis 319 treated with vehicle or with antalarmin, however this apparent difference, did not reach statistical 320 significance (F (2,43) = 1.99, p>0.05; Fig. 5A ). On the other hand, we observed significantly 321 elevated levels of serum adrenocorticotropic hormone (ACTH) in rats that received antalarmin.
322 ANOVA statistical test revealed a significant main effect of drug treatment (F (2,39) = 518, p<0.05;
323 Fig. 5B ). Post hoc tests showed that the groups of rats that received antalarmin was significantly 324 higher that sham and vehicle treated groups (p< 0.05 both comparisons). While anti-325 inflammatory effects of antalarmin have been reported, the short treatment of antalarmin 53 days 326 before sacrifice did not produce any change in IL-6 in peritoneal fluid, which is in direct contact 327 with the endometriotic vesicles (Fig. 5C ). We quantified the mRNA for urocortin and CRH, which are the main agonists of the 339 CRHR1 receptor, within developed endometriosis vesicles in rats from both treatment groups 340 using qRT-PCR. As a comparative parameter, we also quantified the mRNA with the uteri of the 341 same animals and used uteri of sham controls to normalize the data. We observed a significant 342 two-fold increase in CRH for vehicle treated rats, both in uterus (one sample t-test: t= 2.66, d.f.= 343 13, p< 0.05) and vesicles (t= 2.29, d.f.= 13, p< 0.05; Fig. 6A ). However, this increase was not 344 observed in the antalarmin treatment group (Fig. 6A) . In contrast, UCN1 mRNA was not altered 345 in any of the groups measured ( Fig. 6B ). Here we present evidence that a short treatment with the CRHR1 antagonist antalarmin 387 had long-term efficacy in reducing endometriosis with minimal changes in behavior. More 388 importantly, the vesicles that developed were significantly smaller, suggesting that antalarmin 389 interfered with both the establishment and the development of vesicles. We also demonstrated 390 that antalarmin prevented the increase in CRH and CRHR1 mRNA within endometriosis vesicles 391 as compared to vehicle treated rats that lasted for almost 2 months after treatment stopped. This 392 suggests that a short treatment might produce long-lasting effects for the treatment of this 393 disease. To our knowledge, our work provides the first in vivo evidence of efficacy and use of 394 CRHR1 antagonist antalarmin for the treatment of endometriosis.
395
In the present study, only one time point was tested corresponding to a major increase in 396 CRHR1 mRNA, early in endometriosis development, as demonstrated herein. Sampson's theory 397 postulates that retrograde menstruation leads to endometriosis. Based on this theory, during 398 every menstruation, there is opportunity for new endometriosis implants to develop. Therefore, 399 we suggest that in the clinical scenario, treatment with CRHR1 antagonist would need to be used 400 right after laparoscopic surgery or for several years, similar to contraceptive pills, in order to be 401 effective. In our animal model, we observed that about 60% of the implants sites developed into 402 endometriosis vesicles. Perhaps a longer or continuous treatment with the CRHR1 antagonist 403 might have produced a larger decrease in endometriosis vesicle development or even completely 404 abolish it. In the clinical setting, there is a significant lag in the diagnosis of endometriosis, 405 which is on average 7 years after symptoms appear. Our work opens the possibility for future 406 testing of antalarmin or other CRHR1 antagonist at later time points in disease progression.
